Sarepta Therapeutics, Inc.

Develops precision genetic medicines for rare neuromuscular disorders.

SRPT | US

Overview

Corporate Details

ISIN(s):: US8036071004
LEI:
Country:: United States of America
Address:: 215 FIRST STREET, 2142 CAMBRIDGE
Website:: https://www.sarepta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sarepta Therapeutics, Inc. is a global biotechnology company focused on engineering precision genetic medicines to treat rare diseases. The company's primary mission is to develop therapies for conditions with few or no treatment options, with a significant focus on neuromuscular disorders like Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease. Sarepta utilizes advanced scientific platforms, including RNA-targeted technologies, gene therapy, and gene editing. It has multiple FDA-approved treatments and maintains a pipeline of over 40 programs. The company is also focused on accelerating drug development timelines and building large-scale gene therapy manufacturing capacity to support patient access.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sarepta Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sarepta Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Sarepta Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CITIUS ONCOLOGY, INC. Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.	United States of America	CTOR
Citius Pharmaceuticals, Inc. Late-stage biopharma developing critical care products for oncology, infections, and stem cells.	United States of America	CTXR
CJ Bioscience Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.	South Korea	311690
CKD Bio Corp. Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.	South Korea	063160
Clearmind Medicine Inc. Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.	United States of America	CMND
Clearside Biomedical, Inc. Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.	United States of America	CLSD
Clene Inc. Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.	United States of America	CLNN
Climb Bio, Inc. Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.	United States of America	CLYM
CMG Pharmaceutical Co., Ltd. Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.	South Korea	058820
Cocrystal Pharma, Inc. Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.	United States of America	COCP